Passage Bio, Inc. has taken a significant step in its growth strategy by announcing a merger with Remix Therapeutics, Inc. This merger, approved by stockholders at a Special Meeting on November 5, 2026, is poised to enhance Passage Bio's capabilities in the biological products sector, particularly in the development of innovative therapies.
The merger involves a two-step process where Peregrine Merger Sub, Inc., a wholly owned subsidiary of Passage Bio, will first merge with Remix, which will then lead to a second merger with Peregrine Merger Sub II, LLC. This strategic move is expected to create a more robust entity that can better compete in the rapidly evolving biotechnology landscape.
Background
Passage Bio, Inc. is a Delaware-based company focused on developing genetic medicines for rare diseases. It operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). The company trades on the Nasdaq under the ticker symbol PASG. Recent filings include a 10-Q on November 10, 2026, and several 8-Ks detailing various corporate actions and financial updates.
What the Filing Says
According to the SEC filing (accession number 0001140361-26-044947), the merger agreement was further amended on October 5, 2026. The filing states, "Passage Bio is filing this Current Report on Form 8-K to provide certain financial information with respect to the proposed Mergers." It includes unaudited condensed interim financial statements for Remix as of September 30, 2026, and pro forma financial information for the combined companies.
Impact
This merger may significantly affect the competitive dynamics within the biotechnology industry, particularly among companies focused on biological products. By combining resources and expertise, Passage Bio and Remix aim to accelerate the development of new therapies, potentially leading to enhanced market offerings and improved patient outcomes.
What's Next
The filing does not specify what happens next, but it indicates that further regulatory approvals and integration processes will follow the merger announcement. Stakeholders will be closely monitoring the progress of this merger and its implications for the companies involved.
Read Next
Angel Studios CFO Klossner Reports Stock Transactions
Angel Studios reports executive stock transactions
Angel Studios COO Ellis Elizabeth Acquires 81,971 Shares
Angel Studios CEO Harmon Neal Reports Major Stock Transactions
Harmon Jeffrey Reports Significant Stock Transactions
Harmon Jordan Reports Stock Transactions as President of Angel Studios










